Dihydropyrimidine Dehydrogenase Enzyme Deficiency: Clinical and Genetic Assessment of Prevalence in Turkish Cancer Patients
Authors:
- 1 January 2002
- journal article
- Published by Taylor & Francis in Cancer Investigation
- Vol. 20 (3) , 333-339
Abstract
Background: Fluorouracil has been reported to induce severe side-effects in particular subjects who have deficiency in dehydropyrimidine dehyrogenase activity, the major enzyme in the catabolism of fluorouracil. Patients and methods: In this study, we aimed to analyze the heterozygote and homozygote frequencies of dehydropyrimidine dehyrogenase gene mutation in 200 patients receiving fluorouracil based chemotherapy together with the assessment of the toxicity profile of these chemotherapy regimens. Results: According to the results of clinical toxicity assessments, grade 3–4 hematologic toxicity was noted in 12% of the patients. Grade 3 gastrointestinal toxicity was present in 5% of the subjects with no grade 4 side effects. The heterozygote (2q(1−q)) and homozygote (q2) frequencies of dehydropyrimidine dehyrogenase gene mutation were calculated as 1.5% (3/200) and 0.000055% (1/18,043) in the analyzed samples. Conclusion: In this report, for the first time we documented the frequency of dehydropyrimidine dehydrogenase gene mutation in Turkish cancer patients. The determination of enzyme activity in suspected individuals and analysis of other mutations on a population basis would be the next steps for our country.Keywords
This publication has 9 references indexed in Scilit:
- Identification of a four-base deletion (delTCAT 296-299 ) in the dihydropyrimidine dehydrogenase gene with variable clinical expressionHuman Genetics, 1997
- Identification of novel point mutations in the dihydropyrimidine dehydrogenase geneJournal of Inherited Metabolic Disease, 1997
- Dihydropyrimidine dehydrogenase inactivation and 5-fluorouracil pharmacokinetics: allometric scaling of animal data, pharmacokinetics and toxicodynamics of 5-fluorouracil in humansCancer Chemotherapy and Pharmacology, 1996
- Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity.Journal of Clinical Investigation, 1996
- Human Polymorphism in Drug Metabolism: Mutation in the Dihydropyrimidine Dehydrogenase Gene Results in Exon Skipping and Thymine UracilureaDNA and Cell Biology, 1995
- Population study of dihydropyrimidine dehydrogenase in cancer patients.Journal of Clinical Oncology, 1994
- Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy.Journal of Clinical Oncology, 1994
- Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndromeCancer, 1991
- Fluorinated Pyrimidines, A New Class of Tumour-Inhibitory CompoundsNature, 1957